1. Home
  2. EDAP vs PBYI Comparison

EDAP vs PBYI Comparison

Compare EDAP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDAP
  • PBYI
  • Stock Information
  • Founded
  • EDAP 1979
  • PBYI 2010
  • Country
  • EDAP France
  • PBYI United States
  • Employees
  • EDAP N/A
  • PBYI N/A
  • Industry
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • EDAP Health Care
  • PBYI Health Care
  • Exchange
  • EDAP Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • EDAP 113.2M
  • PBYI 126.5M
  • IPO Year
  • EDAP 1997
  • PBYI N/A
  • Fundamental
  • Price
  • EDAP $2.65
  • PBYI $2.83
  • Analyst Decision
  • EDAP Strong Buy
  • PBYI Strong Buy
  • Analyst Count
  • EDAP 2
  • PBYI 1
  • Target Price
  • EDAP $14.00
  • PBYI $7.00
  • AVG Volume (30 Days)
  • EDAP 60.8K
  • PBYI 257.4K
  • Earning Date
  • EDAP 11-07-2024
  • PBYI 10-31-2024
  • Dividend Yield
  • EDAP N/A
  • PBYI N/A
  • EPS Growth
  • EDAP N/A
  • PBYI N/A
  • EPS
  • EDAP N/A
  • PBYI 0.18
  • Revenue
  • EDAP $66,481,303.00
  • PBYI $219,143,000.00
  • Revenue This Year
  • EDAP $9.53
  • PBYI N/A
  • Revenue Next Year
  • EDAP $15.87
  • PBYI N/A
  • P/E Ratio
  • EDAP N/A
  • PBYI $15.55
  • Revenue Growth
  • EDAP 8.79
  • PBYI N/A
  • 52 Week Low
  • EDAP $2.45
  • PBYI $2.13
  • 52 Week High
  • EDAP $8.50
  • PBYI $7.73
  • Technical
  • Relative Strength Index (RSI)
  • EDAP 36.17
  • PBYI 59.52
  • Support Level
  • EDAP $2.56
  • PBYI $2.79
  • Resistance Level
  • EDAP $2.82
  • PBYI $2.93
  • Average True Range (ATR)
  • EDAP 0.17
  • PBYI 0.12
  • MACD
  • EDAP 0.04
  • PBYI 0.04
  • Stochastic Oscillator
  • EDAP 37.04
  • PBYI 80.77

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: